HU197212B - Process for producing pharmaceuticals with antiviral and antitumour effect - Google Patents

Process for producing pharmaceuticals with antiviral and antitumour effect Download PDF

Info

Publication number: HU197212B
Authority: HU; Hungary
Prior art keywords: sodium; acid; xanthate; potassium; adjuvant
Prior art date: 1985-08-02

Application number

HU863351A

Other languages

German (de)

English (en)

Hungarian (hu)

Other versions

HUT42949A (en

Inventor

Gerhard Sauer

Eberhard Amtmann

Klaus W Hummel

Original Assignee

Merz & Co Gmbh & Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-08-02

Filing date

1986-08-01

Publication date

1989-03-28

1986-08-01 Application filed by Merz & Co Gmbh & Co filed Critical Merz & Co Gmbh & Co

1987-09-28 Publication of HUT42949A publication Critical patent/HUT42949A/hu

1989-03-28 Publication of HU197212B publication Critical patent/HU197212B/hu

Links

230000000840 anti-viral effect Effects 0.000 title claims abstract description 40
230000000259 anti-tumor effect Effects 0.000 title claims abstract description 27
239000003814 drug Substances 0.000 title claims abstract 3
238000000034 method Methods 0.000 title claims description 18
230000008569 process Effects 0.000 title claims description 9
230000000694 effects Effects 0.000 title description 12
239000000203 mixture Substances 0.000 claims abstract description 20
ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 claims description 107
238000011282 treatment Methods 0.000 claims description 45
239000002671 adjuvant Substances 0.000 claims description 42
150000001875 compounds Chemical class 0.000 claims description 40
-1 cyclododecyl Chemical group 0.000 claims description 27
239000012991 xanthate Substances 0.000 claims description 23
ZOOODBUHSVUZEM-UHFFFAOYSA-N ethoxymethanedithioic acid Chemical class CCOC(S)=S ZOOODBUHSVUZEM-UHFFFAOYSA-N 0.000 claims description 20
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 19
229910052708 sodium Inorganic materials 0.000 claims description 19
239000011734 sodium Substances 0.000 claims description 19
GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 13
GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 claims description 12
229910052783 alkali metal Inorganic materials 0.000 claims description 12
239000000243 solution Substances 0.000 claims description 12
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 11
229910052700 potassium Inorganic materials 0.000 claims description 11
239000011591 potassium Substances 0.000 claims description 11
125000004432 carbon atom Chemical group C* 0.000 claims description 10
239000003795 chemical substances by application Substances 0.000 claims description 10
150000002763 monocarboxylic acids Chemical class 0.000 claims description 10
239000008194 pharmaceutical composition Substances 0.000 claims description 10
238000002360 preparation method Methods 0.000 claims description 10
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 9
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 9
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 6
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 6
229910019142 PO4 Inorganic materials 0.000 claims description 5
229960003964 deoxycholic acid Drugs 0.000 claims description 5
238000002347 injection Methods 0.000 claims description 5
239000007924 injection Substances 0.000 claims description 5
229940125396 insulin Drugs 0.000 claims description 5
239000002674 ointment Substances 0.000 claims description 5
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
102000004877 Insulin Human genes 0.000 claims description 4
108090001061 Insulin Proteins 0.000 claims description 4
150000001340 alkali metals Chemical class 0.000 claims description 4
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 claims description 4
239000008103 glucose Substances 0.000 claims description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
239000010452 phosphate Substances 0.000 claims description 4
UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 4
230000000699 topical effect Effects 0.000 claims description 4
208000030507 AIDS Diseases 0.000 claims description 3
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
229940009976 deoxycholate Drugs 0.000 claims description 3
KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 3
229940043264 dodecyl sulfate Drugs 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
150000008051 alkyl sulfates Chemical class 0.000 claims description 2
239000002775 capsule Substances 0.000 claims description 2
230000010261 cell growth Effects 0.000 claims description 2
ARUKYTASOALXFG-UHFFFAOYSA-N cycloheptylcycloheptane Chemical group C1CCCCCC1C1CCCCCC1 ARUKYTASOALXFG-UHFFFAOYSA-N 0.000 claims description 2
239000003085 diluting agent Substances 0.000 claims description 2
SVMUEEINWGBIPD-UHFFFAOYSA-N dodecylphosphonic acid Chemical compound CCCCCCCCCCCCP(O)(O)=O SVMUEEINWGBIPD-UHFFFAOYSA-N 0.000 claims description 2
239000000499 gel Substances 0.000 claims description 2
WKMBNCWYZBDIEA-UHFFFAOYSA-N heptoxymethanedithioic acid Chemical compound CCCCCCCOC(S)=S WKMBNCWYZBDIEA-UHFFFAOYSA-N 0.000 claims description 2
238000001802 infusion Methods 0.000 claims description 2
238000007911 parenteral administration Methods 0.000 claims description 2
239000007921 spray Substances 0.000 claims description 2
239000000829 suppository Substances 0.000 claims description 2
239000003826 tablet Substances 0.000 claims description 2
125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims 2
239000007952 growth promoter Substances 0.000 claims 2
DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical group C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims 1
239000012059 conventional drug carrier Substances 0.000 claims 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
229940033355 lauric acid Drugs 0.000 claims 1
206010028980 Neoplasm Diseases 0.000 abstract description 22
241000700605 Viruses Species 0.000 abstract description 17
208000015181 infectious disease Diseases 0.000 abstract description 12
230000008030 elimination Effects 0.000 abstract 1
238000003379 elimination reaction Methods 0.000 abstract 1
230000001575 pathological effect Effects 0.000 abstract 1
238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 57
210000004027 cell Anatomy 0.000 description 51
241001465754 Metazoa Species 0.000 description 25
238000004113 cell culture Methods 0.000 description 16
230000003612 virological effect Effects 0.000 description 15
210000002950 fibroblast Anatomy 0.000 description 13
239000002609 medium Substances 0.000 description 13
241000699666 Mus <mouse, genus> Species 0.000 description 12
238000002474 experimental method Methods 0.000 description 12
108091003079 Bovine Serum Albumin Proteins 0.000 description 11
108020004414 DNA Proteins 0.000 description 11
241000598436 Human T-cell lymphotropic virus Species 0.000 description 11
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
210000004698 lymphocyte Anatomy 0.000 description 9
238000012360 testing method Methods 0.000 description 9
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
239000004480 active ingredient Substances 0.000 description 8
201000010099 disease Diseases 0.000 description 8
239000012091 fetal bovine serum Substances 0.000 description 8
230000005764 inhibitory process Effects 0.000 description 8
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
241000700588 Human alphaherpesvirus 1 Species 0.000 description 7
206010042971 T-cell lymphoma Diseases 0.000 description 7
230000012010 growth Effects 0.000 description 7
210000001161 mammalian embryo Anatomy 0.000 description 7
229940045145 uridine Drugs 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
208000000453 Skin Neoplasms Diseases 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
239000002253 acid Substances 0.000 description 6
230000007541 cellular toxicity Effects 0.000 description 6
230000010076 replication Effects 0.000 description 6
150000003839 salts Chemical class 0.000 description 6
159000000000 sodium salts Chemical class 0.000 description 6
231100000331 toxic Toxicity 0.000 description 6
230000002588 toxic effect Effects 0.000 description 6
238000002054 transplantation Methods 0.000 description 6
210000004881 tumor cell Anatomy 0.000 description 6
206010025323 Lymphomas Diseases 0.000 description 5
206010029098 Neoplasm skin Diseases 0.000 description 5
229930182555 Penicillin Natural products 0.000 description 5
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
230000037396 body weight Effects 0.000 description 5
238000005119 centrifugation Methods 0.000 description 5
230000006378 damage Effects 0.000 description 5
235000014113 dietary fatty acids Nutrition 0.000 description 5
241001493065 dsRNA viruses Species 0.000 description 5
229930195729 fatty acid Natural products 0.000 description 5
239000000194 fatty acid Substances 0.000 description 5
150000004665 fatty acids Chemical class 0.000 description 5
238000009472 formulation Methods 0.000 description 5
230000002401 inhibitory effect Effects 0.000 description 5
229940049954 penicillin Drugs 0.000 description 5
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 5
239000000126 substance Substances 0.000 description 5
HJRJRUMKQCMYDL-UHFFFAOYSA-N 1-chloro-2,4,6-trinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(Cl)C([N+]([O-])=O)=C1 HJRJRUMKQCMYDL-UHFFFAOYSA-N 0.000 description 4
208000003950 B-cell lymphoma Diseases 0.000 description 4
QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 4
DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 4
229910002092 carbon dioxide Inorganic materials 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
238000011534 incubation Methods 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
210000002510 keratinocyte Anatomy 0.000 description 4
230000000394 mitotic effect Effects 0.000 description 4
235000019271 petrolatum Nutrition 0.000 description 4
210000003491 skin Anatomy 0.000 description 4
238000010186 staining Methods 0.000 description 4
229960005322 streptomycin Drugs 0.000 description 4
230000004083 survival effect Effects 0.000 description 4
231100000816 toxic dose Toxicity 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
241000282693 Cercopithecidae Species 0.000 description 3
241000699800 Cricetinae Species 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
102000000588 Interleukin-2 Human genes 0.000 description 3
108010002350 Interleukin-2 Proteins 0.000 description 3
TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 3
108020005088 Superhelical DNA Proteins 0.000 description 3
125000001931 aliphatic group Chemical group 0.000 description 3
238000003556 assay Methods 0.000 description 3
239000001569 carbon dioxide Substances 0.000 description 3
239000012894 fetal calf serum Substances 0.000 description 3
230000002093 peripheral effect Effects 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
235000021317 phosphate Nutrition 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
241000894007 species Species 0.000 description 3
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
239000003104 tissue culture media Substances 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000701822 Bovine papillomavirus Species 0.000 description 2
241000450599 DNA viruses Species 0.000 description 2
241000388186 Deltapapillomavirus 4 Species 0.000 description 2
SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
238000011785 NMRI mouse Methods 0.000 description 2
108010089814 Plant Lectins Proteins 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
238000010306 acid treatment Methods 0.000 description 2
125000000129 anionic group Chemical group 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
239000003443 antiviral agent Substances 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
239000002585 base Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
244000309466 calf Species 0.000 description 2
150000001735 carboxylic acids Chemical class 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
230000000973 chemotherapeutic effect Effects 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
238000011284 combination treatment Methods 0.000 description 2
239000013078 crystal Substances 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
XJWSAJYUBXQQDR-UHFFFAOYSA-M dodecyltrimethylammonium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)C XJWSAJYUBXQQDR-UHFFFAOYSA-M 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
230000035876 healing Effects 0.000 description 2
210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
208000014674 injury Diseases 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
230000002147 killing effect Effects 0.000 description 2
239000003883 ointment base Substances 0.000 description 2
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
239000003726 plant lectin Substances 0.000 description 2
NFFKRJOYWMTDBM-UHFFFAOYSA-M potassium;undecanoate Chemical compound [K+].CCCCCCCCCCC([O-])=O NFFKRJOYWMTDBM-UHFFFAOYSA-M 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
230000007017 scission Effects 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
SZHOJFHSIKHZHA-UHFFFAOYSA-N tridecanoic acid Chemical compound CCCCCCCCCCCCC(O)=O SZHOJFHSIKHZHA-UHFFFAOYSA-N 0.000 description 2
241001529453 unidentified herpesvirus Species 0.000 description 2
DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
230000029812 viral genome replication Effects 0.000 description 2
TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 1
GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical class C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000700198 Cavia Species 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
241000699677 Cricetus cricetus Species 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
VFZRZRDOXPRTSC-UHFFFAOYSA-N DMBA Natural products COC1=CC(OC)=CC(C=O)=C1 VFZRZRDOXPRTSC-UHFFFAOYSA-N 0.000 description 1
GZZPOFFXKUVNSW-UHFFFAOYSA-N Dodecenoic acid Natural products OC(=O)CCCCCCCCCC=C GZZPOFFXKUVNSW-UHFFFAOYSA-N 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
102000004533 Endonucleases Human genes 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
201000008808 Fibrosarcoma Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
206010028116 Mucosal inflammation Diseases 0.000 description 1
201000010927 Mucositis Diseases 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
235000021360 Myristic acid Nutrition 0.000 description 1
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
241000700159 Rattus Species 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
KZENBFUSKMWCJF-UHFFFAOYSA-N [5-[5-[5-(hydroxymethyl)-2-thiophenyl]-2-furanyl]-2-thiophenyl]methanol Chemical compound S1C(CO)=CC=C1C1=CC=C(C=2SC(CO)=CC=2)O1 KZENBFUSKMWCJF-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
150000001449 anionic compounds Chemical class 0.000 description 1
229940121357 antivirals Drugs 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000000211 autoradiogram Methods 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
208000019065 cervical carcinoma Diseases 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
230000005757 colony formation Effects 0.000 description 1
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
QMPPYLFXRKUTOR-UHFFFAOYSA-N decoxymethanedithioic acid Chemical compound CCCCCCCCCCOC(S)=S QMPPYLFXRKUTOR-UHFFFAOYSA-N 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000011549 displacement method Methods 0.000 description 1
TVACALAUIQMRDF-UHFFFAOYSA-N dodecyl dihydrogen phosphate Chemical compound CCCCCCCCCCCCOP(O)(O)=O TVACALAUIQMRDF-UHFFFAOYSA-N 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
235000013399 edible fruits Nutrition 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000013213 extrapolation Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
230000009229 glucose formation Effects 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
230000009036 growth inhibition Effects 0.000 description 1
229910052595 hematite Inorganic materials 0.000 description 1
239000011019 hematite Substances 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
LIKBJVNGSGBSGK-UHFFFAOYSA-N iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Fe+3].[Fe+3] LIKBJVNGSGBSGK-UHFFFAOYSA-N 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
206010025482 malaise Diseases 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
238000007431 microscopic evaluation Methods 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
210000000107 myocyte Anatomy 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
150000003242 quaternary ammonium salts Chemical class 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
235000003441 saturated fatty acids Nutrition 0.000 description 1
150000004671 saturated fatty acids Chemical class 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000004575 stone Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000011421 subcutaneous treatment Methods 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
150000003871 sulfonates Chemical class 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000000946 synaptic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

HU863351A 1985-08-02 1986-08-01 Process for producing pharmaceuticals with antiviral and antitumour effect HU197212B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE3527871		1985-08-02

Publications (2)

Publication Number	Publication Date
HUT42949A HUT42949A (en)	1987-09-28
HU197212B true HU197212B (en)	1989-03-28

Family

ID=6277597

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HU863351A HU197212B (en)	1985-08-02	1986-08-01	Process for producing pharmaceuticals with antiviral and antitumour effect

Country Status (7)

Country	Link
KR (1)	KR860008777A (cs)
AT (1)	AT388499B (cs)
CS (1)	CS275793B6 (cs)
DD (1)	DD286971A5 (cs)
ES (1)	ES2000384A6 (cs)
HU (1)	HU197212B (cs)
PT (1)	PT83127B (cs)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR1140M (fr) *	1961-05-16	1962-02-19	Johnson & Johnson	Composition chimiothérapique a efficacité accrue.
US4164573A (en) *	1975-06-13	1979-08-14	Galinsky Alvin M	Composition and method for making a suppository for introducing a hypoglycemic agent into a mammal
IT1202370B (it) *	1976-07-12	1989-02-09	Hoffmann La Roche	Soluzioni inietabili in cui l'atti vita' emolitica degli agenti di formazione di micelle naturali e' evitata mediante l'aggiunta di lipoidi e relativi prodotti
JPS5940137B2 (ja) *	1976-10-14	1984-09-28	武田薬品工業株式会社	経口投与用医薬組成物
JPS54122719A (en) *	1978-03-16	1979-09-22	Sankyo Co Ltd	Carcinostatic agent for oral administration
JPS56100711A (en) *	1980-01-16	1981-08-12	Teijin Ltd	Pharmaceutical for remedy of uterine cancer
CA1174978A (en) *	1980-11-26	1984-09-25	Arthur Scherm	Xanthates
AR230264A1 (es) *	1980-11-26	1984-03-01	Merz & Co Gmbh & Co	Procedimiento para la obtencion de compuestos de xantato
JPS58124714A (ja) *	1982-01-20	1983-07-25	Yamanouchi Pharmaceut Co Ltd	抗腫瘍物質の油性組成物
US4578391A (en) *	1982-01-20	1986-03-25	Yamanouchi Pharmaceutical Co., Ltd.	Oily compositions of antitumor drugs
DE3218121A1 (de) *	1982-05-14	1983-11-17	Leskovar, Peter, Dr.-Ing., 8000 München	Arzneimittel zur tumorbehandlung

1986
- 1986-08-01 ES ES8600811A patent/ES2000384A6/es not_active Expired - Fee Related
- 1986-08-01 CS CS865798A patent/CS275793B6/cs unknown
- 1986-08-01 KR KR1019860006354A patent/KR860008777A/ko not_active Ceased
- 1986-08-01 AT AT0208786A patent/AT388499B/de not_active IP Right Cessation
- 1986-08-01 HU HU863351A patent/HU197212B/hu not_active IP Right Cessation
- 1986-08-01 PT PT83127A patent/PT83127B/pt not_active IP Right Cessation
- 1986-08-01 DD DD86293361A patent/DD286971A5/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
CS8605798A2 (en)	1990-10-12
KR860008777A (ko)	1986-12-18
AT388499B (de)	1989-06-26
ATA208786A (de)	1988-12-15
CS275793B6 (en)	1992-03-18
DD286971A5 (de)	1991-02-14
HUT42949A (en)	1987-09-28
ES2000384A6 (es)	1991-03-16
PT83127B (pt)	1989-03-30
PT83127A (en)	1986-09-01

Legal Events

Date	Code	Title	Description
1990-06-28	HU90	Patent valid on 900628
1995-01-30	HPC4	Succession in title of patentee	Owner name: CT-HOLDING SA, CH
1998-05-28	HMM4	Cancellation of final prot. due to non-payment of fee

Publication	Publication Date	Title
US8138200B2 (en)	2012-03-20	Compositions and methods for double-targeting virus infections and targeting cancer cells
PT1385498E (pt)	2007-12-14	Ácidos gordos como factores de sobrevivência e activação de neutrófilos
US20200054552A1 (en)	2020-02-20	Medicament for the treatment of viral skin and tumour diseases
HU203201B (en)	1991-06-28	Process for producing antitumoural pharmaceutical composition having synergetic effect
JP5031162B2 (ja)	2012-09-19	ウイルス感染を二重ターゲティングおよびガン細胞をターゲティングするための組成物および方法
EP1156797B1 (en)	2007-10-24	Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
US4851435A (en)	1989-07-25	Antiviral and antitumor xanthate pharmaceutical compositions
US4910224A (en)	1990-03-20	Method of modifying the lipid structure and function of cell membranes and pharmaceutical compositions for use therein
KR100528815B1 (ko)	2005-11-16	장쇄 알코올, 알칸, 지방산 및 아미드로 바이러스를 억제하는 방법
LT3197B (en)	1995-03-27	Use of quinones in the treatmet of cancer or aids
JP2724711B2 (ja)	1998-03-09	医薬品生成物
CA2066155A1 (en)	1992-02-03	Antiviral agent for human immunodeficiency virus
US7309696B2 (en)	2007-12-18	Compositions and methods for targeting cancer cells
JP3176615B2 (ja)	2001-06-18	乾癬症の局所治療剤及びその製法
CN101031288B (zh)	2010-11-03	作为造血作用刺激剂的中链长脂肪醇
DE3625948C2 (cs)	1991-04-18
Parab	2024	Hydroxyurea: Occurrence, uses and side effects
KR970003049B1 (ko)	1997-03-14	혈소판감소증 예방 및 치료제
KR20010108040A (ko)	2001-12-07	항-ｈｉｖ 감염증제 및 ｈｉｖ 감염증의 치료 방법
CS275793B6 (en)	1992-03-18	Production method of the antivirus and antitumour agent
JPH07179347A (ja)	1995-07-18	抗ウイルス組成物
GB2324242A (en)	1998-10-21	Medicaments for treating viral infections
HK1111358B (en)	2012-04-13	Medium-chain length fatty alcohols as stimulators of hematopoiesis